$Summit Therapeutics(SMMT)$ Summit Therapeutics Announced That Data For Its Novel, Potential First-in-class Investigational Bispecific Antibody, Ivonescimab, Will Be Presented At The 2024 European Lung Cancer Congress In Prague, Czech Republic参加了这么多会议，拼命宣传，还不赶紧完成入组，早日把数据读出吧